BioSpace News Archive

Canadian Blood Services and Canada’s COVID-19 Immunity Task Force are releasing new results from their collaborative nine-province SARS-CoV-2 seroprevalence study.

The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-generation biologic medicines

Noveome Biotherapeutics , Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed Ronald K. Poropatich, M.D., M.S., to the company’s Board of Directors.

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Rob Glassman , M.D., to its Board of Directors.

TScan Therapeutics, today announced the closing of an oversubscribed $100 million Series C financing.

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will hold a conference call today, Monday, January 25 at 4:30 pm ET on the Company’s announcement that results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2.

Epilepsy research in North America has received a major boost. Epilepsy Canada, headquartered in Toronto and CURE Epilepsy, based in Chicago, two organizations at the forefront of funding scientific research, have agreed to form a strategic working relationship which formally commenced on January 1, 2021.

The partnership is built around providing greater access to quality, affordable, compassionate health care through shared education, research and clinical integration for urban and rural populations.

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer today announced the closing of a previously announced underwritten public offering of 7,711,284 shares of its common stock at a price of $5.45 per share.